1
• Published June 6, 2025
Antibody-drug conjugates were the topic du jour at this year’s annual meeting of the American Society of Clinical Oncology and the rising trend in cancer care has many in the industry champing at the bit for a piece of the action.
It wasn’t always a sure bet that ADCs would break through the noise, though. The first one approved by the FDA — Mylotarg from Pfizer subsidiary Wyeth for acute leukemia — came to market in 2000. The company…